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Abstract
Introduction: Recently, studies have demonstrated that the addition of bevacizumab to chemotherapy could be associated
with better outcomes in patients with advanced non-small cell lung cancer (NSCLC). However, the benefit seems to be
dependent on the drugs used in the chemotherapy regimens. This systematic review evaluated the strength of data on
efficacy of the addition of bevacizumab to chemotherapy in advanced NSCLC.
Methods: PubMed, EMBASE, and Cochrane databases were searched. Eligible studies were randomized clinical trials (RCTs)
that evaluated chemotherapy with or without bevacizumab in patients with advanced NSCLC. The outcomes included
overall survival (OS), progression-free survival (PFS), response rate (RR), toxicities and treatment related mortality. Hazard
ratios (HR) and odds ratios (OR) were used for the meta-analysis and were expressed with 95% confidence intervals (CI).
Results: We included results reported from five RCTs, with a total of 2,252 patients included in the primary analysis, all of
them using platinum-based chemotherapy regimens. Compared to chemotherapy alone, the addition of bevacizumab to
chemotherapy resulted in a significant longer OS (HR 0.89; 95% CI 0.79 to 0.99; p=0.04), longer PFS (HR 0.73; 95% CI 0.66 to
0.82; p,0.00001) and higher response rates (OR 2.34; 95% CI 1.89 to 2.89; p,0.00001). We found no heterogeneity between
trials, in all comparisons. There was a slight increase in toxicities in bevacizumab group, as well as an increased rate of
treatment-related mortality.
Conclusions: The addition of bevacizumab to chemotherapy in patients with advanced NSCLC prolongs OS, PFS and RR.
Considering the toxicities added, and the small absolute benefits found, bevacizumab plus platinum-based chemotherapy
can be considered an option in selected patients with advanced NSCLC. However, risks and benefits should be discussed
with patients before decision making.
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Introduction
Lung cancer affects approximately 200,000 patients in the
United States and is the leading cause of cancer-related deaths in
both men and women [1]. More than 1.3 million lung cancer
patients die annually worldwide. More than 80% of these patients
have non–small cell lung cancer (NSCLC) [2], and at least 51%
lung cancer patients are diagnosed with metastatic disease.
Palliative chemotherapy increases overall survival and quality of
life when compared to supportive care as stated in a meta-analysis
[3], and these patients have an average survival of 8 to 10 months
when treated with platinum-based regimens [4]. Currently, there
is no universally accepted standard regimen for first-line treatment
of advanced NSCLC, as platinum-based chemotherapy has
reached a plateau on survival benefit that is no longer than 10
months, on average.
Agents that target specific pathways in the development or
progression of NSCLC have shown useful clinical activity.
Vascular endothelial growth factor (VEGF) is a potent endothe-
lial-specific angiogenic factor that is expressed in a wide array of
tumors. In NSCLC, high levels of VEGF expression are
associated with a poor prognosis [5], suggesting that treatment
targeted toward this pathway might be significant therapeutically.
Bevacizumab is a monoclonal antibody with a high affinity for
VEGF, and thereby prevents its interaction with the VEGF
receptor [6].
A randomized phase II trial found that the addition of
bevacizumab to carboplatin-paclitaxel improved response rate
(RR) (31.5% vs 18.8%) and time to progression (7.4 months vs 4.2
months) when compared to chemotherapy alone, in patients with
advanced NSCLC [7]. There was also a nonsignificant improve-
ment in overall survival (OS). In this trial, patients whose tumors
had squamous cell histology were found to be at greater risk for
developing hemoptysis. Because of that, in the subsequent trials
only patients with predominantly non-squamous NSCLC were
studied.
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granted approval for bevacizumab for use in advanced NSCLC
[8], based on data from a phase III trial (E4599) conducted by the
Eastern Cooperative Oncology Group (ECOG) [9,10], which
excluded squamous cell histology. This trial compared carbopla-
tin-paclitaxel with and without bevacizumab in 878 patients, and
the results indicated a significant improvement in RR (35% vs
15%), progression-free survival (PFS) (6.2 vs 4.5 months) and OS
(12.3 vs 10.3 months) related to bevacizumab.
Since there is no standard dose or schedule for bevacizumab in
the treatment of lung cancer, a second randomized phase III trial
(AVAiL) [11,12] compared cisplatin-gemcitabine with or without
bevacizumab, 7.5 mg/kg or 15 mg/kg, in 1,043 patients with
advanced NSCLC. There was a smaller, but still significant
improvement in PFS (6.7 vs 6.5 vs 6.1 months, respectively) and
RR (37.8% vs 34.6% vs 21.6%, respectively) at both doses of
bevacizumab, but without a difference in OS (13.6 vs 13.4 vs 13.1
months, respectively), suggesting that the benefit of bevacizumab
could be dependent on the chemotherapy regimen used. It was
stated that these differences could be only due to AVAiL being
underpowered to detect OS benefits. Indeed, after initiated, the
primary endpoint of AVAiL was amended from OS to PFS,
following presentation of E4599 results.
As the results of clinical trials were not completely consistent,
and none of them was large enough to accurately interpret the
efficacy and safety of bevacizumab in combination with che-
motherapy, the aim of this meta-analysis was to evaluate and to
quantify the effectiveness and safety of bevacizumab in patients
with advanced NSCLC.
Methods
This systematic review was originally completed in the context
of an evidence-based training, developed by the Centre for
Evidences in Oncology (CEVON) workgroup, in the State
University of Campinas (UNICAMP), Brazil. All the evidence
was selected and reviewed by two members of CEVON and
discussed with the group and the coordinator (ADS). All work
produced by CEVON is editorially independent and does not
have any funding source.
Search strategy
A wide search of the main computerized databases of interest
was conducted, including PubMed/MEDLINE, EMBASE, LI-
LACS, ClinicalTrials.gov and CENTRAL. The ASCO, ESMO
and IASLC Meeting websites were also scrutinized. We used a
sensitive search strategy with words related to lung, cancer,
chemotherapy, bevacizumab, and randomized trials in all fields.
For PubMed/MEDLINE we used the following search terms:
(‘‘lung neoplasms’’[MeSH Terms] OR (‘‘lung’’[All Fields] AND
‘‘neoplasms’’[All Fields]) OR ‘‘lung neoplasms’’[All Fields]) AND
(‘‘drug therapy’’[Subheading] OR (‘‘drug’’[All Fields] AND
‘‘therapy’’[All Fields]) OR ‘‘drug therapy’’[All Fields] OR ‘‘drug
therapy’’[MeSH Terms]) AND (‘‘bevacizumab’’[All Fields]) AND
(random*[All Fields]).
All references of relevant articles were scanned and all
additional studies of potential interest were retrieved for further
analysis. Two reviewers analyzed the list of references and
independently selected the studies. The search included literature
published or presented up to December 2010.
Selection criteria
We sought to identify all published randomized controlled
clinical trials with a parallel design comparing chemotherapy with
or without bevacizumab in patients with advanced NSCLC. To
minimize possible bias due to interaction of biologic agents, we
excluded trials or arms containing agents targeted against the
epidermal growth factor receptor (EGFR).
Data extraction
The name of the first author and the year of publication of the
article were used for identification purposes. Two reviewers
independently extracted the data from all included studies. A third
reviewer was consulted to resolve disagreements. The outcomes
analyzed were OS, PFS, RR, incidence of Common Toxicity
Criteria (CTC) scale grade 3/4 toxicities and treatment related
mortality.
The hazard ratios (HRs) of time-to-event data (OS and PFS)
were directly extracted from the original studies or were estimated
indirectly using either the reported number of events and the
corresponding p-value for the log-rank statistics, or by reading off
survival curves as suggested by Parmar and colleagues [13]. The
calculations were carried out using a spreadsheet provided by
Tierney and colleagues [14]. For this, the original survival curves
from electronic publication were enlarged, and data extraction was
based on reading off electronic coordinates for each point of
interest in order to decrease reading errors. The number of events
and number at risk were abstracted for each dichotomous data
comparison evaluated.
Statistical analysis and synthesis
Details regarding the main methodological dimensions empiri-
cally linked to bias as described by Deeks and colleagues [15] were
extracted, and the methodological quality of each selected trial
were assessed by two reviewers (ABL and LTM). These data were
combined in a pre-specified subgroup, and sensitivity analyses
were performed to test the stability of our conclusions.
All meta-analyses were performed using Review Manager 5
(RevMan 5; The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, Denmark) with a random effects
model. Time-to-event outcomes were compared using an HR.
Dichotomous data were compared using an odds ratio (OR).
Respective 95% confidence intervals (CI) were calculated for each
estimate and presented in forest plots. The pooled HR or OR,
symbolized by a solid diamond at the bottom of the forest plot (the
width of which represents the 95% CI) is the best estimate of the
true (pooled) outcome. The effect of the treatment for each single
study was expressed as a ratio of the bevacizumab chemotherapy
arm over the chemotherapy alone arm.
Statistical heterogeneity in the results of the trials was assessed
by the chi-square test [16], and was expressed by the I2 index, as
described by Higgins and colleagues [17]. When considerable
heterogeneity was detected (I2.35%), a possible explanation for it
was pursued. When a reasonable cause was found, a separate
analysis was performed. Publication bias was evaluated with the
Egger’s test [15].
Results
Our systematic search screened 530 trials, and found six
publications related to five randomized clinical trials (2,252
patients) that compared chemotherapy with or without bevacizu-
mab [7,9,11,18–20]. Only the most updated data were included in
the analysis. Other potential eligible studies were single-armed or
involved EGFR inhibitors and were therefore excluded. A
diagram represents the flow of identification and inclusion of
trials (Figure 1), as recommended by the PRISMA statement [21].
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analysis. All but Herbst et al [19] evaluated first-line palliative
therapy. Herbst et al included patients who had progressed during
or after one platinum-based regimen. Details about methodology
potentially linked to bias are described in Table 1. Crossover was
not permitted in the two major phase III trials. Johnson et al’s
phase II trial [7] included patients with squamous cell histology. As
a result of the prohibitive bleeding toxicity in this group, squamous
cell histology became an exclusion criterion in the other trials of
this meta-analysis.
Johnson et al excluded one patient in the experimental group
because of the discovery of CNS metastasis. E4599 excluded 28
patients because of eligibility violations. One patient in the
experimental group in the Herbst et al trial did not receive
bevacizumab, although included in the analysis. All patients in the
AVAiL trial were included in the primary analysis despite 57 patients
receiving no study therapy as a result of eligibility violations, consent
withdrawal, adverse events (AEs) and other reasons. In the present
meta-analysis we used the intention-to-treat (ITT) data from the
trials, when possible. It was not possible to extract ITT data inE4599
trial, which excluded ineligible patients from primary analysis. ITT
data from Nishio et al was not available either, since data was
extracted from meeting presentations.
Chemotherapy regimens included paclitaxel plus carboplatin up
to six cycles [7,9,20], cisplatin plus gemcitabine up to six cycles
[11], and single agent docetaxel or pemetrexed until disease
progression [19]. Drugs were administered on the first day of each
3-week cycle. The dose of bevacizumab was 7.5 mg/kg [7,12] or
15 mg/kg [7,9,12,19,20] on day 1 of each cycle. Particular
features of all trials are described in Table 2.
Overall Survival
The impact of bevacizumab treatment on OS was extracted
directly or estimated indirectly from published data of four trials
included in this review (2,072 patients). Nishio et al’s trial had
immature data, due to short duration of follow-up, and did not
presented OS results.
In the meta-analysis, the HR for OS favored bevacizumab
combination chemotherapy [HR 0.89 (0.79–0.99), p=0.04],
without significant heterogeneity between studies (I
2=18%;
p=0.30) (Figure 2). This result indicates that there is a slight but
significant reduction in mortality (11%) with the addition of
bevacizumabe to chemotherapy.
Evaluating only trials studying first-line therapy, the meta-
analysis showed similar results, however without statistical sig-
nificance [HR 0.90 (0.79–1.01), p=0.08]. We also calculated the
absolute prolongation of survival for patients who were treated with
first-line chemotherapy plus bevacizumab compared with patients
with a predicted survival on platinum-based doublets of 8 months
[4]. The absolute benefit of association of bevacizumab in median
survival in first line therapy was estimated in 26 days (0.88 months).
The sensitivity analyses performed using subgroups linked to
methodological aspects confirmed similar results. Funnel plots did
not show evidence of significant publication bias risk.
Figure 1. Flow of identification and inclusion of trials.
doi:10.1371/journal.pone.0022681.g001
Table 1. Methodological details potentially related to bias.
Authors Year Phase Blindness
Withdrawn
description
Alpha
error
Beta
error
ITT
sr]analysis Multicenter Sponsor
Johnson et al 2004 II No Yes Yes Yes Yes Yes Industry
Sandler et al 2006 III No Yes Yes Yes No Yes Industry
Herbst et al 2007 II Unclear Yes No No Yes Yes Industry
Reck et al 2009 III Yes Yes Yes Yes Yes Yes Industry
Nishio et al 2009 II No Yes No No No Yes No report
ITT: intention-to-treat analysis.
doi:10.1371/journal.pone.0022681.t001
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Progression-free survival was the primary endpoint in four trials.
The meta-analysis showed a significant benefit related to
bevacizumab [HR 0.73 (0.66–0.82), P,0.00001]. Again, there
was no significant heterogeneity between trials (I2=26%; p=0.23)
(Figure 3). Assuming a median PFS of 4 months for patients in
first-line therapy with platinum-based doublets, we estimated an
absolute benefit of 1.4 months for association of bevacizumab to
chemotherapy.
Overall response rates
The results concerning the overall response rates (RR) showed
high heterogeneity between trials (I2=53%; p=0.06). The
inclusion of one trial evaluating bevacizumab added to second-
line therapy could be the cause of this heterogeneity. It might also
be due to the disparate distribution of squamous cell histology
patients in the baseline data of the Johnson et al trial and difficult
response evaluation due to an early toxicity. In fact, pooling the
data only from trials evaluating first-line therapy in non-squamous
NSCLC, meta-analysis showed a less heterogeneous result
(I2=19%; p=0.30), and a significant RR favoring the bevacizu-
mab group [OR 2.34 (1.89–2.89), p,0.00001] (Figure 4).
Toxicities and safety
All studies described some sort of toxicity, however, only some
of the data were consistently described in the articles. Some of the
more clinically relevant grade 3/4 AEs increased by the addition
of bevacizumab to chemotherapy were hypertension [OR, 5.51
(3.17–9.55), p,0.00001], bleeding events [OR 3.16 (1.82–5.48),
p,0.0001] and febrile neutropenia [OR 2.12 (1.19–3.81),
p=0.01], all presented in Figure 5.
Most important, there was a significant increase in deaths
related to treatment associated with the addition of bevacizumab
[OR 1.82 (1.04–3.18), p=0.04] (Figure 6). Most of the deaths in
the bevacizumab group were related to bleeding events,
neutropenia complications and thromboembolic events. The
available data did not provide the opportunity to quantify and
to compare each cause of mortality individually.
Table 2. Description of interventions and patients included.
Author/year Study/arm
Patients
enrolled Setting
Primary
endpoint
ECOG 0,
1(%) Histology
Maintenance of
bevacizumab
(maximum cycles)
Crossover
permitted
Johnson 2004 TP 32 1
st line PFS 93.7 NSCLC Yes (18) Yes
TP+Bev (7.5) 32 96.8
TP+Bev (15) 35 88.5
Sandler 2006 TP 444 1
st line OS 100 Non-squamous
NSCLC
Yes (until disease
progression)
No
TP+Bev (15) 434 100
Herbst 2007 * D or P 41 2
nd line PFS 97.6 Non-squamous
NSCLC
Yes (until disease
progression)
Yes
Do rP +Bev (15) 40 100
Reck 2009 GP 347 1
st line PFS 100 Non-squamous
NSCLC
Yes (until disease
progression)
No
GP+Bev (7.5) 345 100
GP+Bev (15) 351 100
Nishio 2009 TP 59 1
st line PFS NR Non-squamous
NSCLC
Yes (until disease
progression)
NR
TP+Bev (15) 121
NR: no report; GP: gemcitabine 1,250 mg/m
2 plus cisplatin 80 mg/m
2; TP: paclitaxel 200 mg/m
2 plus carboplatin AUC 6; D: docetaxel 75 mg/m
2; P: pemetrexed 500 mg/
m
2; Bev (7.5): bevacizumab 7.5 mg/kg. Bev (15): bevacizumab 15 mg/kg.
*Included patients that had progressed after one platinum-based regimen.
doi:10.1371/journal.pone.0022681.t002
Figure 2. Meta-analysis of overall survival.
doi:10.1371/journal.pone.0022681.g002
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The main finding of the present meta-analysis is the
homogeneous OS improvement provided by the addition of
bevacizumab to chemotherapy when compared to chemotherapy
alone in the advanced NSCLC setting, with an 11% reduction in
risk of death, but with an estimated absolute benefit of less than 1
month in median survival.
The meta-analysis showed also that the addition of bevacizu-
mab to chemotherapy resulted in a significant improvement in
both PFS (absolute benefit of 1.4 months in median) and RR
(absolute difference of 16%). The benefits were consistent and
seemed to be applicable to all patients with non-squamous
NSCLC. However, these outcomes can be considered less
important to patients, and should be validated with quality of
life analysis in order to prove a clear clinical benefit.
Comparing the two phase III trials included in this systematic
review, the E4599 trial demonstrated an important OS benefit
(HR 0.79, p=0.003), while AVAiL failed in this goal (HR 0.93,
p=0.420; HR 1.03, p=0.761; for 7.5 mg/kg and 15 mg/kg
groups, respectively). The authors of the AVAiL trial justified the
results pointing out the greater use of efficacious second-line
therapies, and the slightly more favorable prognostic features in
baseline data compared with the E4599 trial. Moreover, the
difference in OS between the E4599 and AVAiL original
publications was initially explained by preclinical findings showing
that paclitaxel induces circulating endothelial progenitor cells
(CEPs) whereas gemcitabine does not, and that the addition of an
anti-VEGFR2 antibody acts synergistically only in combination
with CEP-mobilizing chemotherapeutic agents [22]. However,
these findings were generated in preclinical tumor models, and
have not been confirmed in clinical trials.
In fact, the absence of heterogeneity between the results in OS
meta-analysis suggests that the AVAil trial was not powered to find
the small difference obtained in OS. The results suggest that the
addition of bevacizumab to cisplatin-based chemotherapy slightly
prolongs OS of advanced NSCLC patients, independently of the
regimen used.
The present study has the typical limitations of the meta-
analytical methodology. Our findings and interpretations were
limited by the quality and quantity of data available. An analysis of
individual patient data would be more powerful to confirm our
findings. Another source of concern is the possible existence of
some unpublished studies, which could lead to potential publica-
tion bias. However, we found no indication of such bias by using
statistical methods designed to detect it.
The toxicities added by bevacizumab, including fatal adverse
events are a great concern. A recent systematic review with meta-
analysis of 16 trials found that the addition of bevacizumab to
chemotherapy, compared with chemotherapy alone, was asso-
ciated with increased treatment-related mortality, in patients with
a variety of advanced solid tumors [23].
The risk of severe toxicity in patients with lung neoplasms may
be particularly increased in elderly patients, as stated in an
unspecified retrospective analysis of E4599 [24]. Nevertheless, a
subanalysis of the safety and efficacy of bevacizumab in 610 elderly
(.65 years) patients in SAiL, a large phase IV trial with 2,172
patients, showed no significant difference in AEs and outcomes in
this subgroup [25].
One of the most prominent yet reversible AEs related to
bevacizumab was hypertension, which was reported to be somewhat
manageable [26]. The VEGF antagonism decreases nitric oxide
production and leads to constriction of the vasculature and a
reduction in sodium ion renal excretion, which ultimately leads to
Figure 3. Meta-analysis of progression-free survival.
doi:10.1371/journal.pone.0022681.g003
Figure 4. Meta-analysis of overall response rates in first-line therapy (non-squamous NCSLC).
doi:10.1371/journal.pone.0022681.g004
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consequence of vascular rarefaction, caused by the inhibition of
angiogenic growth factors required to construct new capillaries and
recruit endothelial progenitor cells [26,29]. An interesting subset
analysis of E4599 suggested that hypertension onset during treatment
with bevacizumab may be associated with improved outcomes [30].
This trend was also observed in SAiL phase IV trial [31]. However,
predictive biomarkers for response are not yet available for
bevacizumab.
In three more recently analyzed studies, patients with squamous
cell carcinoma, or a history of therapeutic anticoagulation,
hemoptysis, or brain metastases were excluded to minimize the
risk of pulmonary or intracerebral hemorrhage, based on results
from Johnson et al. Although bleeding events are a concern, severe
pulmonary hemorrhage was an uncommon event, as confirmed by
the SAiL study [32,33]. Preliminary data from ARIES (6.1 month
median follow-up), a large observational cohort study that
comprised 1,031 patients, also suggest a poor correlation between
Figure 5. Meta-analysis of grade 3/4 toxicities.
doi:10.1371/journal.pone.0022681.g005
Figure 6. Meta-analysis of deaths related to treatment.
doi:10.1371/journal.pone.0022681.g006
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risk of pulmonary hemorrhage [34]. A recent retrospective
exploratory analysis by Besse et al [35] concluded that patients
with CNS metastases are at similar risk of developing cerebral
hemorrhage, independent of bevacizumab therapy. In fact,
ARIES showed that none of the 67 patients with brain metastasis
at baseline developed CNS hemorrhage [34]. In the SAiL and
ARIES trials, there was no increase in bleeding in patients
receiving concurrent bevacizumab and fulldose anticoagulation
therapy.
Notably, our study showed a small increase in risk of treatment-
related death, in patients receiving the association of bevacizumab
to chemotherapy. The difficulty in find a pre-established group of
patients at great risk of serious adverse events could be
challenging, in clinical practice. Based in recent evidence, all
patients treated with bevacizumab should be monitored carefully
for bleeding, gastrointestinal tract perforation, and neutropenia.
In conclusion, this meta-analysis demonstrates that bevacizu-
mab combined with standard platinum-based chemotherapy
doublets in the first-line setting leads to a small but significantly
improved OS, PFS and RR for patients with advanced non-
squamous NSCLC. Taking into account the toxicities added and
the small increase in risk of treatment-related death, bevacizumab
plus platinum-based chemotherapy can be considered an option in
selected patients with advanced NSCLC. However, benefits and
risks should be discussed with patients before decision making.
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